Healthcare provider profile · identity verified

Anna Roth Wilkins, MD

Family Practice · FORT COLLINS, CO · NPI 1306037726

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	839	249
Levothyroxine Sodium	Levothyroxine Sodium	592	166
Losartan Potassium	Losartan Potassium	529	151
Amlodipine Besylate	Amlodipine Besylate	350	111
Lisinopril	Lisinopril	335	97
Omeprazole	Omeprazole	304	97
Gabapentin	Gabapentin	287	85
Rosuvastatin Calcium	Rosuvastatin Calcium	234	70
Metformin Hcl Er	Metformin Hcl	210	68
Metformin Hcl	Metformin Hcl	159	49
Metoprolol Succinate	Metoprolol Succinate	146	41
Hydrochlorothiazide	Hydrochlorothiazide	143	46
Simvastatin	Simvastatin	141	42
Sertraline Hcl	Sertraline Hcl	139	37
Montelukast Sodium	Montelukast Sodium	133	41
Meloxicam	Meloxicam	131	42
Metoprolol Tartrate	Metoprolol Tartrate	124	32
Trazodone Hcl	Trazodone Hcl	124	32
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	113	22
Duloxetine Hcl	Duloxetine Hcl	110	26
Pantoprazole Sodium	Pantoprazole Sodium	97	33
Tamsulosin Hcl	Tamsulosin Hcl	96	27
Ozempic	Semaglutide	94	19
Potassium Chloride	Potassium Chloride	92	34
Fluticasone Propionate	Fluticasone Propionate	90	45
Jardiance	Empagliflozin	82	24
Albuterol Sulfate Hfa	Albuterol Sulfate	81	46
Citalopram Hbr	Citalopram Hydrobromide	81	25
Alendronate Sodium	Alendronate Sodium	79	27
Furosemide	Furosemide	79	32
Tramadol Hcl	Tramadol Hcl	79	14
Escitalopram Oxalate	Escitalopram Oxalate	74	22
Allopurinol	Allopurinol	72	19
Synthroid	Levothyroxine Sodium	70	16
Pregabalin	Pregabalin	66	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	65	18
Fluoxetine Hcl	Fluoxetine Hcl	59	17
Eliquis	Apixaban	56	18
Famotidine	Famotidine	54	16
Tizanidine Hcl	Tizanidine Hcl	51	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	49	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	15
Pravastatin Sodium	Pravastatin Sodium	49	17
Diclofenac Sodium	Diclofenac Sodium	46	13
Trulicity	Dulaglutide	45	suppressed
Rybelsus	Semaglutide	44	suppressed
Glipizide	Glipizide	42	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	18
Spironolactone	Spironolactone	39	12
Warfarin Sodium	Warfarin Sodium	38	12
Cephalexin	Cephalexin	36	34
Clonazepam	Clonazepam	36	suppressed
Estradiol	Estradiol	34	13
Glimepiride	Glimepiride	34	11
Ezetimibe	Ezetimibe	33	12
Mounjaro	Tirzepatide	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	23
Chlorthalidone	Chlorthalidone	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Atenolol	Atenolol	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	12
Lamotrigine	Lamotrigine	30	suppressed
Lorazepam	Lorazepam	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Propranolol Hcl	Propranolol Hcl	29	12
Celecoxib	Celecoxib	28	suppressed
Diazepam	Diazepam	27	suppressed
Bupropion Xl	Bupropion Hcl	25	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	25	11
Carvedilol	Carvedilol	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	20
Finasteride	Finasteride	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Methylprednisolone	Methylprednisolone	20	18
Ondansetron Odt	Ondansetron	20	14
Vitamin D2	Ergocalciferol (Vitamin D2)	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Azelastine Hcl	Azelastine Hcl	16	suppressed
Baclofen	Baclofen	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Amoxicillin	Amoxicillin	15	14
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Promethazine Hcl	Promethazine Hcl	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Levetiracetam Er	Levetiracetam	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Ramipril	Ramipril	12	suppressed
Trimethoprim	Trimethoprim	12	suppressed
Lovastatin	Lovastatin	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error